Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: Neuroprotective effects of Cerebrolysin

Acta Neuropathologica

Volumn 117, Issue 6, 2009, Pages 699-712

  Ubhi, Kiren ^a   Rockenstein, Edward ^a   Doppler, Edith ^c   Mante, Michael ^a   Adame, Anthony ^a   Patrick, Christina ^a   Trejo, Margarita ^a   Crews, Leslie ^b   Paulino, Amy ^a   Moessler, Herbert ^c   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EBEWE Pharmaceuticals Research Division   (Austria)

Author keywords

Alzheimer's; Amyloid precursor protein; Hippocampus; Kinase; Phosphorylation; Viral vector

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CEREBROLYSIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PARVOVIRUS VECTOR; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE TRANSFER; HIPPOCAMPUS; MOUSE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AMINO ACIDS; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL LINE, TUMOR; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIPPOCAMPUS; HUMANS; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RATS; RECEPTORS, CELL SURFACE; TAU PROTEINS;

EID: 67349281559     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-009-0505-4     Document Type: Article

References (89)

1. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 13:43-54. doi: 10.1111/j.1468-1331.2006.01222.x
2. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582-590. doi: 10.1046/j.1471-4159.2003.01879.x
3. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115-9129. doi: 10.1523/JNEUROSCI.2361-07.2007
4. Brion JP, Tremp G, Octave JN (1999) Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am J Pathol 154:255-270
5. Caccamo A, Oddo S, Tran LX, LaFerla FM (2007) Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170:1669-1675. doi: 10.2353/ajpath.2007.061178
6. Chana G, Landau S, Beasley C, Everall IP, Cotter D (2003) Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: Evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 53:1086-1098. doi: 10.1016/ S0006-3223(03)00114-8
7. Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I, Cherner M, Lazzaretto D, Heaton R, Ellis R, Masliah E (2006) Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67:1486-1489. doi: 10.1212/01.wnl.0000240066.02404.e6
8. Cho JH, Johnson GV (2003) Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 278:187-193. doi: 10.1074/jbc.M206236200
9. Cho JH, Johnson GV (2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 88:349-358
10. Davies P, Ghanbari H, Issacs A, Dickson D, Mattiace L, Rosado M, Vincent I (1993) TG3: A better antibody that Alz-50 for the visualization of Alzheimer-type neuronal pathology. Soc Neurosci Abstr 19:1636
11. DeKosky S, Scheff S (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27:457-464. doi: 10.1002/ana.410270502
12. Delobel P, Lavenir I, Fraser G, Ingram E, Holzer M, Ghetti B, Spillantini MG, Crowther RA, Goedert M (2008) Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol 172:123-131. doi: 10.2353/ajpath.2008.070627
13. Duff K (2001) Transgenic mouse models of Alzheimer's disease: Phenotype and mechanisms of pathogenesis. Biochem Soc Symp 67:195-202
14. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG (2000) Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 62:463-472. doi: 10.1002/ 1097-4547(20001101)62:3<463::AID-JNR16>3.0.CO;2-7
15. Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: Short-term study. Neurosci Lett 202:1-4. doi: 10.1016/0304-3940(95)12240-0
16. Goedert M, Hasegawa M (1999) The tauopathies: Toward an experimental animal model. Am J Pathol 154:1-6
17. Gomez-Ramos A, Dominguez J, Zafra D, Corominola H, Gomis R, Guinovart JJ, Avila J (2006) Inhibition of GSK3 dependent tau phosphorylation by metals. Curr Alzheimer Res 3:123-127. doi: 10.2174/156720506776383059
18. Gotz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, Goedert M (1995) Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14:1304-1313
19. Gotz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276:529-534. doi: 10.1074/jbc.M006531200
20. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495. doi: 10.1126/science.1062097
21. Hashimoto M, Sagara Y, Everall IP, Mallory M, Everson A, Langford D, Masliah E (2002) Fibroblast growth factor 1 regulates signaling via the GSK3β pathway: Implications for neuroprotection. J Biol Chem 277:32985-32991. doi: 10.1074/jbc.M202803200
22. Hong M, Chen DC, Klein PS, Lee VM (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272:25326-25332. doi: 10.1074/jbc.272.40.25326
23. Hutton M, Lewis J, Dickson D, Yen S, McGowan E (2001) Analysis of tauopathies with transgenic mice. Trends Mol Med 7:467-470. doi: 10.1016/ S1471-4914(01)02123-2
24. Hyman B, Gomez-Isla T (1994) Alzheimer's disease is a laminar regional and neural system specific disease, not a global brain disease. Neurobiol Aging 15:353-354. doi: 10.1016/0197-4580(94)90031-0
25. Hyman BT, Augustinack JC, Ingelsson M (2005) Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. Biochim Biophys Acta 1739:150-157
26. Illenberger S, Zheng-Fischhofer Q, Preuss U, Stamer K, Baumann K, Trinczek B, Biernat J, Godemann R, Mandelkow EM, Mandelkow E (1998) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: Implications for Alzheimer's disease. Mol Biol Cell 9:1495-1512
27. Jicha GA, Bowser R, Kazam IG, Davies P (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48:128-132. doi: 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E
28. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925-937. doi: 10.1016/S0896-6273(03)00124-7
29. Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM (2006) Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13:517-527. doi: 10.1016/j.ymthe.2005.10.008
30. Koo E, Lansbury PJ, Kelly J (1999) Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 96:9989-9990. doi: 10.1073/pnas.96.18.9989
31. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA (2005) Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 11:164-169. doi: 10.1016/ j.molmed.2005.02.008
32. Lee VM (1996) Regulation of tau phosphorylation in Alzheimer's disease. Ann N Y Acad Sci 777:107-113. doi: 10.1111/j.1749-6632.1996.tb34408.x
33. Lee VM, Trojanowski JQ (1999) Neurodegenerative tauopathies: Human disease and transgenic mouse models. Neuron 24:507-510. doi: 10.1016/ S0896-6273(00)81106-X
34. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159. doi: 10.1146/annurev.neuro.24.1.1121
35. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491. doi: 10.1126/ science.1058189
36. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK (2006) Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45:3134-3145. doi: 10.1021/bi051635j
37. Li T, Paudel HK (2006) Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 45:3125-3133. doi: 10.1021/ bi051634r
38. Mallory M, Honer W, Hsu L, Johnson R, Masliah E (1999) In vitro synaptotrophic effects of Cerebrolysin in NT2N cells. Acta Neuropathol 97:437-446. doi: 10.1007/s004010051012
39. Mandelkow EM, Biernat J, Drewes G, Gustke N, Trinczek B, Mandelkow E (1995) Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging 16:355-362. doi: 10.1016/0197-4580(95)00025-A discussion 362-353
40. Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, Mandelkow E (1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci 777:96-106. doi: 10.1111/j.1749-6632.1996.tb34407.x
41. Masliah E (1995) Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 10:509-519
42. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W (1999) Cerebrolysin ameliorates performance deficits and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 62:239-245
43. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287:1265-1269. doi: 10.1126/science.287.5456.1265
44. McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5:333-338. doi: 10.2174/1566523054064995
45. Mi K, Johnson GV (2006) The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 3:449-463. doi: 10.2174/156720506779025279
46. Michel G, Mercken M, Murayama M, Noguchi K, Ishiguro K, Imahori K, Takashima A (1998) Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells. Biochim Biophys Acta 1380:177-182
47. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20:4050-4058
48. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102:6990-6995. doi: 10.1073/ pnas.0500466102
49. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39:409-421. doi: 10.1016/ S0896-6273(03)00434-3
50. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332. doi: 10.1016/j.neuron.2004.07.003
51. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281:39413-39423. doi: 10.1074/jbc.M608485200
52. Paxinos G, Franklin K (2003) The mouse brain in stereotaxic coordinates. Academic Press, NY
53. Peel AL, Klein RL (2000) Adeno-associated virus vectors: Activity and applications in the CNS. J Neurosci Methods 98:95-104. doi: 10.1016/ S0165-0270(00)00183-7
54. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5:301-308
55. Perez M, Ribe E, Rubio A, Lim F, Moran MA, Ramos PG, Ferrer I, Isla MT, Avila J (2005) Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation. Neuroscience 130:339-347. doi: 10.1016/j.neuroscience.2004.09.029
56. Poorkaj P, Grossman M, Steinbart E, Payami H, Sadovnick A, Nochlin D, Tabira T, Trojanowski JQ, Borson S, Galasko D, Reich S, Quinn B, Schellenberg G, Bird TD (2001) Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol 58:383-387. doi: 10.1001/archneur.58.3.383
57. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 74:1587-1595. doi: 10.1046/ j.1471-4159.2000.0741587.x
58. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750-754. doi: 10.1126/science.1141736
59. Rockenstein E, McConlogue L, Tan H, Power M, Masliah E, Mucke L (1995) Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 270:28257-28267. doi: 10.1074/ jbc.270.47.28257
60. Rockenstein E, Mallory M, Mante M, Sisk A, Masliah E (2001) Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of Ab1-42. J Neurosci Res 66:573-582. doi: 10.1002/jnr.1247
61. Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, Masliah E (2002) Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl 62:327-336
62. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E (2003) The neuroprotective effects of Cerebrolysin trade mark in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 110:1313-1327. doi: 10.1007/ s00702-003-0025-7
63. Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M, Moessler H, Masliah E (2005) Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm 112:269-282. doi: 10.1007/s00702-004-0181-4
64. Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E (2006) Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res 83(7):1252-1261
65. Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E (2006) Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res 83:1252-1261. doi: 10.1002/jnr.20818
66. Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E (2007) Effects of Cerebrolysin trade mark on neurogenesis in an APP transgenic model of Alzheimer's disease. Acta Neuropathol 113:265-275. doi: 10.1007/ s00401-006-0166-5
67. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:1981-1991. doi: 10.1523/ JNEUROSCI.4321-06.2007
68. Ruther E, Ritter R, Apecechea M, Freitag S, Windisch M (1994) Efficacy of Cerebrolysin in Alzheimer's disease. In: Jellinger K, Ladurner G, Windisch M (eds) New trends in the diagnosis and therapy of Alzheimer's disease. Springer, Vienna, pp 131-141
69. Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer's type (SDAT). Pharmacopsychiatry 27:32-40. doi: 10.1055/s-2007-1014271
70. Ryder J, Su Y, Liu F, Li B, Zhou Y, Ni B (2003) Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 312:922-929. doi: 10.1016/j.bbrc.2003.11.014
71. Schubert D, Heinemann S, Carlisle W, Tarikas H, Kimes B, Patrick J, Steinbach JH, Culp W, Brandt BL (1974) Clonal cell lines from the rat central nervous system. Nature 249:224-227. doi: 10.1038/249224a0
72. Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J (2007) Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol 152:959-979. doi: 10.1038/sj.bjp.0707471
73. Selkoe DJ, Schenk D (2003) Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-584. doi: 10.1146/annurev.pharmtox.43.100901.140248
74. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192:106-113. doi: 10.1016/j.bbr.2008.02.016
75. Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15:157-168
76. Sinha S, Anderson J, John V, McConlogue L, Basi G, Thorsett E, Schenk D (2000) Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci 920:206-208
77. Spencer B, Rockenstein E, Crews L, Marr R, Masliah E (2007) Novel strategies for Alzheimer's disease treatment. Expert Opin Biol Ther 7:1853-1867. doi: 10.1517/14712598.7.12.1853
78. Takahashi M, Yasutake K, Tomizawa K (1999) Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons. J Neurochem 73:2073-2083
79. Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 9:309-317
80. Tatebayashi Y, Lee MH, Li L, Iqbal K, Grundke-Iqbal I (2003) The dentate gyrus neurogenesis: A therapeutic target for Alzheimer's disease. Acta Neuropathol 105:225-232
81. Terry R, Hansen L, Masliah E (1994) Structural basis of the cognitive alterations in Alzheimer disease. In: Terry R, Katzman R (eds) Alzheimer disease. Raven Press, New York, pp 179-196
82. Trojanowski J, Schmidt M, Shin R-W, Bramblett G, Rao D, Lee V-Y (1993) Altered Tau and neurofilament proteins in neurodegenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias. Brain Pathol 3:45-54. doi: 10.1111/j.1750-3639.1993.tb00725.x
83. Trojanowski JQ, Lee VM (1994) Phosphorylation of neuronal cytoskeletal proteins in Alzheimer's disease and Lewy body dementias. Ann N Y Acad Sci 747:92-109
84. Veinbergs I, Mante M, Mallory M, Masliah E (2000) Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm Suppl 59:273-280
85. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101:1172-1184. doi: 10.1111/j.1471-4159.2006.04426.x
86. Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21:719-727. doi: 10.1016/S0197-4580(00)00157-3
87. Wei ZH, He QB, Wang H, Su BH, Chen HZ (2007) Meta-analysis: The efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm 114:629-634. doi: 10.1007/s00702-007-0630-y
88. Wen Y, Yang SH, Liu R, Perez EJ, Brun-Zinkernagel AM, Koulen P, Simpkins JW (2007) Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta 1772:473-483
89. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, Proud CG (2001) The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: Potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 355:609-615